EXPERIENCE WITH TOCILIZUMAB, AN INTERLEUKIN 6 INHIBITOR, USED FOR THE TREATMENT OF GIANT CELL ARTERITIS WITH SEVERE COMORBIDITY
Giant cell arteritis (GCA), formerly known as Horton's disease, is among the most common diseases from a group of systemic vasculitides; its clinical significance is complemented with the potential involvement of the coronary arteries, aorta, and cranial arteries with development of ischemic op...
Main Authors: | T. V. Beketova, M. A. Ushakova, N. Yu. Nikishina, A. N. Khelkovskaya-Sergeeva, E. V. Nikolaeva, E. G. Sazhina, T. M. Novoselova, E. L. Nasonov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2018-05-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2529 |
Similar Items
-
INNOVATIVE TREATMENTS FOR TAKAYASU’S ARTERITIS: A FOCUS ON INTERLEUKIN-6 INHIBITORS. THE AUTHORS’ EXPERIENCE WITH TOCILIZUMAB AND A REVIEW OF LITERATURE
by: T. V. Beketova, et al.
Published: (2017-10-01) -
Advances in the Treatment of Giant Cell Arteritis
by: Santos Castañeda, et al.
Published: (2022-03-01) -
Tongue necrosis secondary to giant cell arteritis, successfully treated with tocilizumab: a case report
by: Young Min Cho, et al.
Published: (2023-05-01) -
Patients’ Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study
by: Cyril Dumain, et al.
Published: (2022-05-01) -
The efficacy of interleukin-6 inhibitor tocilizumab for takayasu’s arteritis, after insufficient response to previous treatment with glucocorticoids, methotrexate, cyclophosphamide, fludarabine. (A case report)
by: V. N. Antipova, et al.
Published: (2021-01-01)